Agilent Technologies. has been granted a patent for methods to assess cancer cell cytolysis using a cell-substrate impedance monitoring device. The method involves adding patient-derived immune effector cells to cancer target cells, monitoring impedance changes, and determining the effectiveness of cell killing through various analytical techniques. GlobalData’s report on Agilent Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agilent Technologies, Microfluidics automation was a key innovation area identified from patents. Agilent Technologies's grant share as of July 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Cytolysis assessment method for cancer cells using impedance
The granted patent US12066428B2 outlines a method for assessing the cytolysis of cancer cells using a cell-substrate impedance monitoring device. The method involves several steps, starting with the introduction of cancer target cells and patient-derived effector immune cells into a well equipped with an electrode array. The impedance of the cell-substrate is monitored before and after the addition of effector cells, allowing for the derivation of various impedance-based parameters. Effectiveness in killing target cells is determined through multiple analytical approaches, including area under the curve (AUC) comparisons, linear regression analysis, and the calculation of a killing time 50 (KT50) value, which indicates the time required to achieve 50% cytolysis.
Further claims detail the methodology for analyzing the potency of effector cells by comparing slopes of impedance-based curves against different concentrations of effector cells. The patent also describes the potential addition of compounds that may influence the effectiveness of effector cell activity, including checkpoint inhibitors and bispecific engagers. These compounds can be tested in control wells to assess their impact on the cytolytic activity of effector cells. The method provides a comprehensive framework for evaluating immune responses against cancer cells, with implications for personalized cancer therapies and the development of new treatment strategies.
To know more about GlobalData’s detailed insights on Agilent Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
